Metabolism Enhancement by Laser Therapy

NCT ID: NCT06899958

Last Updated: 2025-03-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-04-01

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a single-center, open-label pilot study to determine the effect of large area fractional laser treatment (LAFLT) on adults' metabolic profile.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The current research project aims to investigate the effects of large-area fractional laser treatment (LAFLT) on body weight, metabolism, and body composition. Prior research suggests that treating large skin areas with fractional laser therapy may stimulate metabolism and promote weight loss. The MIRIA laser, an FDA-approved fractional laser, is widely used for skin aging, acne scarring, and wrinkle reduction and will be used to evaluate these potential metabolic effects.

Subjects aged 18-60 with a BMI of 25-30 will undergo three fractional laser treatments on the abdomen and thighs over 36 weeks, with sessions every four weeks. The study includes six total visits, incorporating photography, non-invasive imaging, x-rays, blood draws, and two optional biopsies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metabolism Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fractional Laser treatment

Large Area Fractional Laser treatments to the abdomen and thighs using the MIRIA laser.

Group Type EXPERIMENTAL

Fractional Laser

Intervention Type DEVICE

Three fractional laser treatments to the abdomen and thighs at 4 week intervals.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fractional Laser

Three fractional laser treatments to the abdomen and thighs at 4 week intervals.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 18- 60 years of age;
2. BMI between 25.0 and 30 kg/m2;
3. Subjects must be in good general health, based on answers provided during the screening visit;
4. Subject must be able and willing to provide written informed consent and comply with the requirements of the study protocol.
5. Females of childbearing potential must be willing and able to use a medically highly effective form of birth control during the entire study.

Exclusion Criteria

1. Participation in another investigational drug or device clinical trial in the past 30 days;
2. Currently pregnant or pregnancy within the past 6 months or currently breastfeeding;
3. Have a history of drug or alcohol abuse in the past 3 years or have reported habitual alcohol intake greater than 2 standard drinks per day (e.g., 2 beers, 2 glasses of wine, or 2 mixed drinks);
4. Planning or currently participating in a weight loss program;
5. Plan to change daily diet or level of physical activity;
6. Intake of medication that may affect body weight such as GLP-1 receptor agonists, amitriptyline, bupropion, thyroid medications, etc.;
7. History of cancer which required lymph node biopsy or dissection;
8. Weight loss or gain of 10 kg or more in the past 6 months;
9. History of diabetes mellitus or cardiac disease;
10. Intake of hormone replacement therapy (HRT) in the last 6 months;
11. Infection, surgery, or history of trauma or laser treatment to the treatment area in the past 6 months;
12. Presence of any skin disease on the abdomen or thighs;
13. Have birthmarks, tattoos, scars, or any other disfiguration of the skin in the abdomen or thighs;
14. Presence of sunburn or tan in the abdomen or thighs;
15. Use of any topical application of retinoids in the past 6 weeks on the abdomen or thighs or intake of systemic retinoids in the past 6 months;
16. Use of any prescription topical medication, such as corticosteroids or hydroquinone on the abdomen or thighs in the past 6 weeks;
17. History of keloid formation or hypertrophic scarring;
18. History of bariatric surgery or other major weight-loss procedures;
19. History of abdominal liposuction, abdominoplasty or CoolSculpting;
20. Known allergy to lidocaine or other local anesthetics;
21. The investigator believes that the subject is an unsuitable candidate to participate in the study, receive laser treatment, or would be placed at risk by participating in the study.
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Massachusetts General Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Maria Alora

Director, MGH Clinical Unit for Research Trials in Skin

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

MGH Clinical Unit for Research Trials & Outcomes in Skin

Boston, Massachusetts, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Maria Alora, MD

Role: CONTACT

617-726-4454

Alicia Van Cott, NP

Role: CONTACT

617-726-4454

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Alicia Van Cott, NP

Role: primary

617-726-4454

References

Explore related publications, articles, or registry entries linked to this study.

Salma N, Wang-Evers M, Karasik D, Yerevanian A, Downs H, Luo T, Doyle AE, Tannous Z, Cacicedo JM, Manstein D. Large area fractional laser treatment of mouse skin increases energy expenditure. iScience. 2023 Dec 7;27(1):108677. doi: 10.1016/j.isci.2023.108677. eCollection 2024 Jan 19.

Reference Type BACKGROUND
PMID: 38213618 (View on PubMed)

May M, Schindler C, Engeli S. Modern pharmacological treatment of obese patients. Ther Adv Endocrinol Metab. 2020 Jan 22;11:2042018819897527. doi: 10.1177/2042018819897527. eCollection 2020.

Reference Type BACKGROUND
PMID: 32030121 (View on PubMed)

Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med. 2022 Jan;70(1):5-13. doi: 10.1136/jim-2021-001952. Epub 2021 Oct 27.

Reference Type BACKGROUND
PMID: 34706925 (View on PubMed)

Bettini S, Belligoli A, Fabris R, Busetto L. Diet approach before and after bariatric surgery. Rev Endocr Metab Disord. 2020 Sep;21(3):297-306. doi: 10.1007/s11154-020-09571-8.

Reference Type BACKGROUND
PMID: 32734395 (View on PubMed)

Patsouris D, Qi P, Abdullahi A, Stanojcic M, Chen P, Parousis A, Amini-Nik S, Jeschke MG. Burn Induces Browning of the Subcutaneous White Adipose Tissue in Mice and Humans. Cell Rep. 2015 Nov 24;13(8):1538-44. doi: 10.1016/j.celrep.2015.10.028. Epub 2015 Nov 12.

Reference Type BACKGROUND
PMID: 26586436 (View on PubMed)

Manstein D, Herron GS, Sink RK, Tanner H, Anderson RR. Fractional photothermolysis: a new concept for cutaneous remodeling using microscopic patterns of thermal injury. Lasers Surg Med. 2004;34(5):426-38. doi: 10.1002/lsm.20048.

Reference Type BACKGROUND
PMID: 15216537 (View on PubMed)

Laubach HJ, Tannous Z, Anderson RR, Manstein D. Skin responses to fractional photothermolysis. Lasers Surg Med. 2006 Feb;38(2):142-9. doi: 10.1002/lsm.20254.

Reference Type BACKGROUND
PMID: 16392146 (View on PubMed)

Gotkin RH, Sarnoff DS, Cannarozzo G, Sadick NS, Alexiades-Armenakas M. Ablative skin resurfacing with a novel microablative CO2 laser. J Drugs Dermatol. 2009 Feb;8(2):138-44.

Reference Type BACKGROUND
PMID: 19213229 (View on PubMed)

Prignano F, Ricceri F, Bonan P, Cannarozzo G, Campolmi P. Induction of apoptosis by fractional CO2 laser treatment. J Cosmet Laser Ther. 2012 Dec;14(6):267-71. doi: 10.3109/14764172.2012.738820.

Reference Type BACKGROUND
PMID: 23058108 (View on PubMed)

Bogdan Allemann I, Kaufman J. Fractional photothermolysis--an update. Lasers Med Sci. 2010 Jan;25(1):137-44. doi: 10.1007/s10103-009-0734-8.

Reference Type BACKGROUND
PMID: 19787413 (View on PubMed)

Porter C, Tompkins RG, Finnerty CC, Sidossis LS, Suman OE, Herndon DN. The metabolic stress response to burn trauma: current understanding and therapies. Lancet. 2016 Oct 1;388(10052):1417-1426. doi: 10.1016/S0140-6736(16)31469-6.

Reference Type BACKGROUND
PMID: 27707498 (View on PubMed)

Knuth CM, Auger C, Jeschke MG. Burn-induced hypermetabolism and skeletal muscle dysfunction. Am J Physiol Cell Physiol. 2021 Jul 1;321(1):C58-C71. doi: 10.1152/ajpcell.00106.2021. Epub 2021 Apr 28.

Reference Type BACKGROUND
PMID: 33909503 (View on PubMed)

Jeschke MG. The hepatic response to thermal injury: is the liver important for postburn outcomes? Mol Med. 2009 Sep-Oct;15(9-10):337-51. doi: 10.2119/molmed.2009.00005. Epub 2009 Apr 10.

Reference Type BACKGROUND
PMID: 19603107 (View on PubMed)

Hew JJ, Parungao RJ, Shi H, Tsai KH, Kim S, Ma D, Malcolm J, Li Z, Maitz PK, Wang Y. Mouse models in burns research: Characterisation of the hypermetabolic response to burn injury. Burns. 2020 May;46(3):663-674. doi: 10.1016/j.burns.2019.09.014. Epub 2019 Oct 10.

Reference Type BACKGROUND
PMID: 31606314 (View on PubMed)

Jeschke MG, van Baar ME, Choudhry MA, Chung KK, Gibran NS, Logsetty S. Burn injury. Nat Rev Dis Primers. 2020 Feb 13;6(1):11. doi: 10.1038/s41572-020-0145-5.

Reference Type BACKGROUND
PMID: 32054846 (View on PubMed)

Stanojcic M, Abdullahi A, Rehou S, Parousis A, Jeschke MG. Pathophysiological Response to Burn Injury in Adults. Ann Surg. 2018 Mar;267(3):576-584. doi: 10.1097/SLA.0000000000002097.

Reference Type BACKGROUND
PMID: 29408836 (View on PubMed)

Yu YM, Tompkins RG, Ryan CM, Young VR. The metabolic basis of the increase of the increase in energy expenditure in severely burned patients. JPEN J Parenter Enteral Nutr. 1999 May-Jun;23(3):160-8. doi: 10.1177/0148607199023003160.

Reference Type BACKGROUND
PMID: 10338224 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2025P000547

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

LLLT to Reduce Low Back Pain
NCT06007976 RECRUITING NA